In re Revance Therapeutics, Inc. Securities Litigation

  1. March 23, 2026

    Revance Investors Ink $17M Deal In Take-Private Offer Suit

    Dermal fillers company Revance Therapeutics Inc. and two of its executives have agreed to a $17 million settlement to end claims the company hurt investors after the value of a take-private tender offer was negotiated down following allegations that Revance had breached a distribution deal with another company.

  2. January 06, 2025

    Biotech Co. Revance Faces Suit After Tender Offer Weakens

    Biotechnology company Revance Therapeutics Inc. and two of its executives face a proposed investor class action alleging the company hurt investors after the value of a take-private tender offer was negotiated down following allegations that Revance had breached a distribution deal with another company.